#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Heart failure with preserved ejection fraction and high prevalence of central adiposity


Authors: Ján Murín
Authors‘ workplace: I. interná klinika LF UK a UNB, Nemocnica Staré Mesto, Bratislava
Published in: Diab Obez 2026; 26(1): 19-25
Category: Reviews

Overview

An integral feature of patients with heart failure and preserved ejection fraction (HFpEF) is an expansion of fat mass. While body mass index (BMI) is the most common anthropometric measure of obesity, a measure of central adiposity (the Waist-to-Height Ratio –⁠ WHtR) focuses on body fat content and distribution. WHtR is not distorted by bone or muscle mass, sex or ethnicity and it is particularly relevant in HFpEF. The PARAGON-HF trial randomized 4 796 patients with heart failure and ejection fraction ≥ 45 % to valsartan or to sacubitril/valsartan. The current work characterizes the association of BMI and WHtR with clinical features, outcomes and the response to neprilysin inhibition. About half (49 %) of the participants were considered obese by BMI (≥ 30 kg/m2), but nearly every patient (96 %) had central adiposity (WHtR ≥ .5). Among patients who were not obese (BMI < 30 kg/m2), 860 (37 %) had marked central adiposity (WHtR ≥ .6). Higher BMI and WHtR were both associated with higher risk of total heart failure hospitalization, but as compared with BMI, WHtR was linearly associated with heart failure outcomes and identified a higher proportion of patients who had a particularly elevated risk (i.e. 30 % or greater). An obesity-survival paradox (i.e. improved outcomes in those with greater adiposity) was apparent with BMI in unadjusted analyses, but it was not observed with WHtR. Although neprilysin inhibition appeared to have greater effects on heart failure outcomes in patients with higher BMI and WHtR, analyses of interaction with obesity metrics did not show significant heterogeneity across the range of values for adiposity. In PARAGON-HF trial, in contrast with BMI, nearly every patient with HFpEF had central adiposity (assessed by WHtR), and the risks of adverse heart failure events were more robustly related to WHtR. These data challenge the current reliance on BMI as an appropriate metric of adiposity, and they suggest that –⁠ rather than obesity-related HFpEF being regarded as a select HFpEF subgroup –⁠ central adiposity is ubiquitous feature of HFpEF.

Keywords:

obesity – body mass index – heart failure with preserved ejection fraction – angiotensin receptor-neprilysin inhibitor – waist-to-height ratio


Sources
  1. Anker SD, Butler J, Filippatos G et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-preserved trial. Eur J Heart Fail 2020; 22(12): 2383–2392. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.2064>.
  2. Adamson C, Kondo T, Jhund PS et al. Dapagliflozin for heart failure according to body mass index:the DELIVER trial. Eur Heart J 2022; 43)41): 4406–4417. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehac481>.
  3. Packer M, Lam CSP, Lund LH et al. Characterization of the inflammatory –⁠ metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail 2020; 22(9): 1551–1567. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.1902>.
  4. Packer M. Drugs that ameliorate epicardial adipose tissue inflammation may have discordant effects in heart failure with a preserved ejection fraction as compared with a reduced ejection fraction. J Card Fail 2019; 25(12): 986–1003. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cardfail.2019.09.002>.
  5. Dawson LP, Carrington MJ, Haregu T et al. Ten-year risk equations for incident heart failure in established atherosclerotic cardiovascular disease populations. J Am Heart Assoc 2024; 13(11): e034254. Dostupné z DOI: <http://dx.doi.org/10.1161/JAHA.124.034254>.
  6. Borlaug BA, Kitzman DW, Davies MJ et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med 2023; 29(9): 2358–2365. Dostupné z DOI: <http://dx.doi.org/10.1038/s41591–023–02526-x>.
  7. Packer M, Zile MR, Kramer CM et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025; 392(5): 427–437. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2410027>.
  8. Rush EC, Goedecke JH, Jennings C et al. BMI, fat and muscle differences in urban women of five ethnicities from two countries. Int J Obes (Lond) 2007; 31(8): 1232–1239. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.ijo.0803576>.
  9. Castro-Barquero S, Casas R, Rimm EB et al. Loss of visceral fat is associated with a reduction in inflammatory status in patients with metabolic syndrome. Mol Nutr Food Res 2023; 67(4): e2200264. Dostupné z DOI: <http://dx.doi.org/10.1002/mnfr.202200264>.
  10. Mukherjee AG, Renu K, Gopalakrishnan AV et al. Epicardial adipose tissue and cardiac lipotoxicity: a review. Life Sci 2023; 328 : 121913. Dostupné z DOI: <http://dx.doi.org/10.1016/j.lfs.2023.121913>. Retraction in: Retraction notice to “Epicardial adipose tissue and cardiac lipotoxicity: A review” Life Sci 2025; 372 : 123630. Dostupné z DOI: <http://dx.doi.org/10.1016/j.lfs.2025.123630>.
  11. Mohammed SF, Hussain S, Mirzoyev SA et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015; 131(6): 550–559. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.114.009625>.
  12. Edston E. A correlation between the weight of visceral adipose tissue and selected anthropometric indices: an autopsy study. Clin Obes 2013; 3(3–4): 84–89. Dostupné z DOI: <http://dx.doi.org/10.1111/cob.12021>.
  13. Ashwell M, Gibson S. Waist-to-height ratio as an indicator of „early health risk:“ simpler and more predictive than using a „matrix“ based on BMI and waist circumference. BMJ Open 2016; 6(3): e010159. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjopen-2015–010159>.
  14. Yalcin T, Oguz SH, Bayraktar M et al. Anthropometric measurements and serum TNF-alpha, IL-6 and adiponectin in type 2 diabetes. Diabetol Int 2021; 13(2): 396–406. Dostupné z DOI: <http://dx.doi.org/10.1007/s13340–021–00553-y>.
  15. Oguntade AS, Taylor H, Lacey B et al. Adiposity, fat-free mass and incident heart failure in 500 000 individuals. Open Heart 2024; 11(2): e002711. Dostupné z DOI: <http://dx.doi.org/10.1136/openhrt-2024–002711>.
  16. Solomon SD, McMurray JJV, Anand IS et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381(17): 1609–1620. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1908655>.
  17. Gibson S, Ashwell M. A simple cut-off for waist-to-height ratio (0.5) can act as an indicator for cardiometabolic risk: recent data from adults in the health survey for England. Br J Nutr 2020; 123(6): 681–690. Dostupné z DOI: <http://dx.doi.org/10.1017/S0007114519003301>.
  18. Peikert A, Vaduganathan M, Claggett BL et al. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial. Eur Heart J 2025; 46(25): 2372–2390. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaf057>. Erratum in: Eur Heart J 2025; 46(43): 4582. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaf512>.
  19. Packer M. The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation and heart failure with a preserved ejection fraction. Eur J Heart Fail 2018; 20(11): 1567–1569. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.1294>.
  20. Obokata M, Reddy YNW, Pislaru SV et al. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017; 136(1): 6–19. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.116.026807>.
  21. Barbaro G, Piedimonte A, Podagrosi M et al. Epicardial adipose tissue and signs of metabolic syndrome in children. Eat Weight Disord 2016; 21(2): 269–276. Dostupné z DOI: <http://dx.doi.org/10.1007/s40519–015–0221–0>.
  22. Sorimachi H, Omote K, Omar M et al. Sex and central obesity in heart failure with preserved ejection fraction. Eur J Heart Fail 2022; 24(8): 1359–1370. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.2563>.
  23. Butt JH, Petrie MC, Jhund PS et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J 2023; 44(13): 1136–1153. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehad083>.
  24. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6(12): 1008–1010. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jchf.2018.08.007>.
  25. Conte M, Petraglia L, Poggio P et al. Inflammation and cardiovascular diseases in the elderly: the role of epicardial adipose tissue. Front Med (Lausanne) 2022; 9 : 844266. Dostupné z DOI: <http://dx.doi.org/10.3389/fmed.2022.844266>.
  26. Packer M. Derangements in adrenergic-adipokine signaling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction. Eur J Heart Fail 2018; 20(5): 873–878. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.1167>.
  27. Packer M. Leptin-aldosteron-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation 2018; 137(15): 1614–1631. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032474>.
  28. Mehra MR, Uber PA, Park MH et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43(9): 1590–1595. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2003.10.066>.
  29. Moriconi D, Antonioli L, Masi S et al. Glomerular hyperfiltration in morbid obesity: role of the inlammasome signaling. Nephrology (Carlton) 2022; 27(8): 673–680. Dostupné z DOI: <http://dx.doi.org/10.1111/nep.14077>.
  30. Hall JE, Mouton AJ, da Silva AA eta al. Obesity, kidney dysfunction and inflammation: interactions in hypertension. Cardiovasc Res 2021; 117(8): 1859–1876. Dostupné z DOI: <http://dx.doi.org/10.1093/cvr/cvaa336>.
  31. Xu S, Ma J, Zheng Y et al. Para-perirenal fat thickness is associated with reduced glomerular filtration rate regardless of other obesity-related indicators in patients with type 2 diabetes mellitus. PLos One 2023; 18(10): e0293464. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0293464>.
  32. Liu L, Wang Y, Zhang W et al. Waist height ratio predicts chronic kidney disease: a systematic review and meta-analysis, 1998–2019. Arch Public Health 2019; 77 : 55. Dostupné z DOI: <http://dx.doi.org/10.1186/s13690–019–0379–4>.
  33. Morales E, Porrini E, Martin-Taboada M et al. Renoprotective role of bariatric surgery in patients with established chronic kidney disease. Clin Kidney J 2020; 14(9): 2037–2046. Dostupné z DOI: <http://dx.doi.org/10.1093/ckj/sfaa266>.
  34. Reddy YNV, Carter RE, Obokata M et al. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018; 138(9): 861–870. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034646>.
  35. Mandviwala TM, Basra SS, Khalid U et al. Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. Int J Obes (Lond) 2020; 44(7): 1561–1567. Dostupné z DOI: <http://dx.doi.org/10.1038/s41366–020–0563–1>.
  36. Li S, Zheng Y, Huang Y et al. Association of body mass index and prognosis in patients with HFpEF: a dose-response meta-analysis. Int J Cardiol 2022; 361 : 40–46. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2022.05.018>.
  37. Sperrin M, Candlish J, Badrick E et al. Collider bias is only a partial explanation for the obesity paradox. Epidemiology 2016; 27(4): 525–530. Dostupné z DOI:<http://dx.doi.org/10.1097/EDE.0000000000000493>.
  38. Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol 2017; 70(22): 2739–2749. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2017.09.1111>. Erratum in: J Am Coll Cardiol 2018; 71(9): 1059. Dostupné z DOI:<http://dx.doi.org/10.1016/j.jacc.2018.02.003>.
  39. Anker SD, Butler J, Filippatos G et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385(16): 1451–1461. Dostupné z DOI:<http://dx.doi.org/10.1056/NEJMoa2107038>.
  40. Solomon SD, McMurray JJV, Vaduganathan M et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Enl J Med 2024; 391(16): 1475–1485. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2407107>.
  41. Kramer CM, Borlaug BA, Zile M MR et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. Jam Coll Cardiol 2025; 85(7): 699–706. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2024.11.001>.
  42. Packer M, Kitzman DW. Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, neprilysin and sodium-glucose cotransporter-2. JACC Heart Fail 2018; 6(8): 633–639. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jchf.2018.01.009>.
  43. Packer M. Obesity-associated heart failure as a theoretical target for treatment with mineralocorticoid receptor antagonists. JAMA Cardiol 2018; 3(9): 883–887. Dostupné z DOI: <http://dx.doi.org/10.1001/jamacardio.2018.2090>.
  44. Elkholey K, Papadimigtriou L, Butler J et al. Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction. Am J Cardiol 2021; 146 : 36–47. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2021.01.018>.
  45. Pan R, Zhang Y, Wang R et al. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. PLoS One 2022; 17(12): e0279889. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0279889>.
  46. Standeven KF, Hess K, Carter AM et al. Neprilysin obesity and the metabolic syndrome. Int J Obes (Lond) 2011; 35(8): 1031–1040. Dostupné z DOI: <http://dx.doi.org/10.1038/ijo.2010.227>.
  47. Ceyhan BFO. Epicardial fat thickness in patients with gestational diabetes mellitus and its association wih T-terminal pro-brain natriuretic peptide. Eur Rev Med Pharmacol Sci 2024; 28(3): 1044–1051. Dostupné z DOI: <http://dx.doi.org/10.26355/eurrev_202402_35340>.
  48. Daniels MA, Fischer-Posovszky P, Boschmann M et al. Atrial natriuretic peptide and leptin interactions in healthy men. Front Endocrinol (Lausanne) 2023; 14 : 1195677. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2023.1195677>.
  49. Wang L, Tang Y, Herman MA et al. Pharmacologic blockade of the natriuretic peptide clearance receptor promotes weight loss and enhances insulin sensitivity in type 2 diabetes. Transl Res 2023; 255 : 140–151. Dostupné z DOI: <http://dx.doi.org/10.1016/j.trsl.2022.12.005>.
Labels
Diabetology Obesitology

Article was published in

Diabetes and obesity

Issue 1

2026 Issue 1
Popular this week
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#